Home › Research › Treatments
Real-world experience with lecanemab therapy for Alzheimer’s disease in the Intermountain West
Curd BC, Zubrick C, Cliatt Brown CJ, Sorweid MK, Dehoney SB, Anzai Y, Minoshima S, Parks AL et al.. medRxiv, 2025-10-02
Topic: Drug trials: efficacy and safety
INTRODUCTION Lecanemab is a monoclonal antibody targeting amyloid plaques that has been approved for the treatment of Alzheimer’s disease. Here, we report on the clinical history and outcomes of the first 70 patients at the University of Utah to receive amyloid-removal therapy. METHODS This is a retrospective analysis of patients treated with lecanemab over a 26-month period. We extracted patient data from charts and analyzed demographics, health history, and clinical details with outcomes on lecanemab treatment. RESULTS In total, we observed 14 cases of ARIA, which was significantly associated with ApoE genotype. Zero cases of ARIA were symptomatic, and there was no association between geographical location and adverse effects. DISCUSSION Our study examined the safety and tolerability of centralized lecanemab administration across a widely distributed region and suggests that use of distributed infusion sites increases access to disease-modifying treatment without significant increase in risk.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Curd, B. C., Zubrick, C., Cliatt Brown, C. J., Sorweid, M. K., Dehoney, S. B., Anzai, Y., et al. (2025). Real-world experience with lecanemab therapy for Alzheimer’s disease in the Intermountain West. medRxiv. https://doi.org/10.1101/2025.09.30.25337002
Vancouver
Curd BC, Zubrick C, Cliatt Brown CJ, Sorweid MK, Dehoney SB, Anzai Y, et al. Real-world experience with lecanemab therapy for Alzheimer’s disease in the Intermountain West. medRxiv. 2025. doi:10.1101/2025.09.30.25337002.
BibTeX
@article{curd2025-b62fc105,
author = {Curd, B. C. and Zubrick, C. and Cliatt Brown, C. J. and Sorweid, M. K. and Dehoney, S. B. and Anzai, Y. and Minoshima, S. and Parks, A. L. and others},
title = {{Real-world experience with lecanemab therapy for Alzheimer’s disease in the Intermountain West}},
journal = {medRxiv},
year = {2025},
doi = {10.1101/2025.09.30.25337002},
url = {https://doi.org/10.1101/2025.09.30.25337002}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- RESULTS In total, we observed 14 cases of ARIA, which was significantly associated with ApoE genotype.
- DISCUSSION Our study examined the safety and tolerability of centralized lecanemab administration across a widely distributed region and suggests that use of distributed infusion sites increases access to disease-modifying treatment without significant increase in risk.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants70
- Evidence strengthLow
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 26 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, effect reported and randomised / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 16 of the 62 points we could judge it on, which is 26 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 70 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 16 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 16 of the 62 points we could judge it on is 26 out of 100. |
| Total | 26 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related studies in Treatments
Also tagged “aducanumab”
332 studies in the library carry the topic tag “aducanumab”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 332 tagged studies.